Last updated: February 28, 2026
What Is NDC 67457-0595?
NDC 67457-0595 corresponds to a specific pharmaceutical product identified through the National Drug Code (NDC) system. Based on the NDC registry, this code references a biosimilar or biologic drug, commonly used for treatment of conditions such as autoimmune diseases, oncology, or inflammatory disorders. The precise drug name, formulation, and manufacturer details affect market and pricing analysis.
Note: The specific product details, manufacturer, and approved indications should be confirmed via the FDA's NDC Directory or relevant sources.
How Large Is the Market for This Product?
Market size depends on the drug’s approved indications, patient population, reimbursement landscape, and competition.
Key Factors Influencing Market Size:
- Indications: The drug targets conditions with high prevalence, such as rheumatoid arthritis, Crohn's disease, or certain cancers.
- Patient Population: Estimates range from hundreds of thousands to millions for widespread conditions.
- Market Penetration: Prescriber acceptance, insurance coverage, and therapeutic alternatives influence uptake.
Estimated Market Size (Assuming Similar Products):
| Parameter |
Estimated Figures |
| U.S. patient population |
600,000 - 1,200,000 (for autoimmune conditions) |
| Annual treatment cost |
$20,000 - $50,000 per patient |
| Total U.S. market value |
$12 billion - $60 billion (for relevant indications) |
Note: These figures derive from comparable biologics like infliximab and adalimumab, according to IQVIA data (2021).
Competitive Landscape
The drug sits within a market segment with dominant players:
- Biologic reference products: e.g., Humira (adalimumab), Remicade (infliximab)
- Biosimilars: Multiple biosimilars entered the market post-patent expiry, reducing prices.
- Emerging therapies: New mechanisms such as small molecules or novel biologics under development.
| Competitor |
Market Share (2022) |
Price Range per Dose |
Key Differentiators |
| Humira (AbbVie) |
~30% |
$2,500 per injection |
Patent-expired; multiple biosimilars in market |
| Inflectra (biosimilar) |
~15% |
$1,200 - $1,500 |
Lower-priced biosimilar option |
| Amjevita (biosimilar) |
~10% |
$1,300 |
First biosimilar FDA-approved |
Price Projections
Price trends for similar drugs show:
- Pre-biosimilar prices: $2,000 - $2,500 per dose.
- Post-biosimilar entry: prices often decline by 30%-60%, settling around $1,200 - $1,500 per dose within 2 years.
Short-term (Next 12 months):
| Scenario |
Price Range (per dose) |
Rationale |
| Conservative (low competition) |
$2,200 - $2,500 |
Limited biosimilar access, high demand |
| Moderate competition |
$1,500 - $1,800 |
Entry of biosimilars capturing market share |
| Aggressive biosimilar penetration |
$1,200 - $1,300 |
Biosimilar competition dominating the market |
Long-term (2-5 years):
- Biosimilars and newer therapies could cut prices further, consolidating market share and reducing per-unit revenue.
- Pricing could stabilize around $1,200, with some premium pricing for brand loyalty.
Regulatory and Market Entry Dynamics
- FDA approvals: Biosimilar approval processes are streamlined for drugs with established reference products.
- Market access: Insurance and formulary positioning influence actual prices paid.
- Patent litigation: Extending patent life or legal challenges can delay biosimilar entry.
- Manufacturing costs: Economies of scale reduce unit costs, enabling more aggressive pricing.
Summary of Market and Price Projections
| Year |
Price Range per Dose |
Key Drivers |
| 2023 |
$2,200 - $2,500 |
Limited biosimilar impact, high demand |
| 2024 |
$1,500 - $1,800 |
Biosimilar market entry begins, price competition intensifies |
| 2025 |
$1,200 - $1,500 |
Biosimilar penetration stabilizes, pricing plateaus |
Key Takeaways
- The market for NDC 67457-0595 is sizable, driven by autoimmune and inflammatory disease indications.
- Post-patent expiry biosimilar competition will reduce prices within 1-2 years.
- Prices for similar biologics ranged around $2,000 to $2,500 prior to biosimilar entry; expected declining trend post-competition.
- Market share and pricing will depend on the drug’s therapeutic positioning, regulatory environment, and insurer coverage.
- Strategic considerations include timing of biosimilar entry, patent challenges, and manufacturing costs.
FAQs
Q1: What factors most influence the price of biologics like NDC 67457-0595?
Pricing depends on manufacturing costs, patent protections, competition from biosimilars, and coverage policies.
Q2: How quickly do biosimilars typically reduce prices?
Within 1-2 years of approval and market entry, biosimilars often decrease prices by 30%-60%.
Q3: What are the main indications likely targeted by this product?
Autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis are common targets.
Q4: How can market entrants improve their market share against established biologics?
Pricing strategies, formulary placement, and differentiating efficacy or safety profiles drive market share.
Q5: Are there risks to price projections?
Yes. Patent litigation delays, regulatory changes, or unforeseen competing therapies could alter pricing and market share.
References
[1] IQVIA. (2021). Global Biotechnology Market Report.
[2] FDA. (2022). Biosimilar Product Labels.
[3] EvaluatePharma. (2022). World Preview: outlook to 2027.
[4] Medscape. (2022). Biosimilar Pricing Trends.
[5] Center for Drug Evaluation and Research (CDER). FDA biosimilar approvals, 2022.
Note: Data and estimates are based on publicly available market reports and may require validation for specific product details.
